Element Capital Management LLC bought a new stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 318,230 shares of the biotechnology company’s stock, valued at approximately $17,706,000. Element Capital Management LLC owned about 0.49% of Sarepta Therapeutics as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also recently modified their holdings of the company. Hall Laurie J Trustee grew its position in shares of Sarepta Therapeutics by 2,430.8% in the fourth quarter. Hall Laurie J Trustee now owns 3,290 shares of the biotechnology company’s stock valued at $224,000 after purchasing an additional 3,160 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Sarepta Therapeutics by 39.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 977 shares during the period. Prentiss Smith & Co. Inc. purchased a new position in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $199,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $217,000. Finally, Aperio Group LLC purchased a new position in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $219,000. Institutional investors and hedge funds own 84.98% of the company’s stock.
A number of equities analysts have weighed in on SRPT shares. BidaskClub raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, December 25th. Zacks Investment Research lowered shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 5th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, January 9th. JPMorgan Chase reaffirmed an “overweight” rating and set a $75.00 price target (up from $63.00) on shares of Sarepta Therapeutics in a report on Wednesday, February 21st. Finally, Barclays reissued a “hold” rating and set a $55.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, January 23rd. Four investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $78.87.
Shares of SRPT traded down $1.12 during mid-day trading on Friday, hitting $71.74. The company’s stock had a trading volume of 759,523 shares, compared to its average volume of 1,241,583. The stock has a market capitalization of $4,661.52, a P/E ratio of -43.74 and a beta of 1.29. The company has a debt-to-equity ratio of 0.54, a current ratio of 13.91 and a quick ratio of 12.96. Sarepta Therapeutics Inc has a fifty-two week low of $28.14 and a fifty-two week high of $84.37.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.05). The business had revenue of $57.30 million during the quarter, compared to analyst estimates of $57.33 million. Sarepta Therapeutics had a negative return on equity of 30.59% and a negative net margin of 32.79%. The business’s revenue for the quarter was up 961.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.71) EPS. equities research analysts forecast that Sarepta Therapeutics Inc will post -1.18 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “318,230 Shares in Sarepta Therapeutics Inc (SRPT) Purchased by Element Capital Management LLC” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/08/element-capital-management-llc-takes-17-71-million-position-in-sarepta-therapeutics-inc-srpt.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.